Genomic Health (GHDX) Releases Earnings Results, Beats Expectations By $0.05 EPS

Genomic Health (GHDX) reported quarterly earnings results on Wednesday, May-4-2016. The company said it had a profit of $-0.19 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.05. Analysts had a consensus of $-0.24. The company posted revenue of $80.89 million in the period, compared to analysts expectations of $78.13 million. The company’s revenue was up 18.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.30 EPS.

Many Wall Street Analysts have commented on Genomic Health. Shares were Reiterated by Canaccord Genuity on Feb 11, 2016 to “Buy” and Lowered the Price Target to $ 38 from a previous price target of $44 .

Genomic Health opened for trading at $26.48 and hit $27.35 on the upside on Monday, eventually ending the session at $27.23, with a gain of 3.61% or 0.95 points. The heightened volatility saw the trading volume jump to 1,81,959 shares. Company has a market cap of $898 M.

In a different news, on Feb 11, 2016, James J Vaughn (Chief Commercial Officer) sold 3 shares at $28.00 per share price. According to the SEC, on Jan 15, 2016, Randall S Livingston (director) sold 1,250 shares at $32.14 per share price. On Jan 14, 2016, Kimberly J Popovits (President and CEO) sold 5,000 shares at $30.34 per share price, according to the Form-4 filing with the securities and exchange commission.

Genomic Health Inc. is a healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The Company offers its Oncotype DX tests as a clinical laboratory service where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score which it calls a Recurrence Score for invasive breast cancer and colon cancer a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score (GPS) for prostate cancer. The Company’s Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR) in standard tumor pathology specimens to provide tumor-specific information or the oncotype of a tumor. Its offerings also include Oncotype DX Breast Cancer Test Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test.

Genomic Health

Leave a Reply

Genomic Health - Is it time to Sell?

Top Brokerage Firms are advising their investors on Genomic Health. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.